Clinical trial · Interventional
Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases
A Pilot Study of the Efficacy of Levetiracetam in Patients With Seizures From Brain Metastases
NCT00415376CI-TRIAL-00006947withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Unable to accrue subjects
Summary
Brief summary (as posted)
RATIONALE: Anticonvulsant drugs, such as levetiracetam, may help control seizures caused by brain metastases. PURPOSE: This clinical trial is studying the side effects and how well levetiracetam works in treating patients with seizures caused by brain metastases.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
| Seizure | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| levetiracetam | Drug | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Seizure control (lack of seizure activity)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor * Pathological confirmation of brain metastasis is not required provided the clinical and neuroradiographic picture is typical * Has had at least one prior seizure due to brain metastasis PATIENT CHARACTERISTICS: * Life expectancy ≥ 12 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 10 g/dL * BUN \< 5 times upper limit of normal (ULN) * Creatinine \< 5 times ULN * Bilirubin \< 1.5 times ULN * AST and ALT ≤ 3 times ULN * Alkaline phosphatase ≤ 2 times ULN * No allergy to levetiracetam PRIOR CONCURRENT THERAPY: * Prior levetiracetam allowed provided it was initiated within the past 14 days * Other concurrent anticonvulsant monotherapy allowed provided therapy was initiated within the past 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.